APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global GLP-1 Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025184 pages

Choose your research edition.

Industry ResearchGLP-1 Drugs Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drugs Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal GLP-1 Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global GLP-1 Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for GLP-1 Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for GLP-1 Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of GLP-1 Drugs include AstraZeneca, Eli Lilly, GSK, Novo Nordisk, Sanofi, Shanghai Renhui Biopharmaceutical, Sino Biopharm and Huadong Medicine, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Drugs Segment by Company

AstraZeneca

Eli Lilly

GSK

Novo Nordisk

Sanofi

Shanghai Renhui Biopharmaceutical

Sino Biopharm

Huadong Medicine

GLP-1 Drugs Segment by Type

Albiglutide

Exenatide

Beinaglutide

Dulaglutide

Liraglutide

Lixisenatide

Semaglutide

GLP-1 Drugs Segment by Application

Type 2 Diabetes

Obesity

GLP-1 Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of GLP-1 Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of GLP-1 Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of GLP-1 Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Drugs Industry Trends Table 2. GLP-1 Drugs Industry Drivers Table 3. GLP-1 Drugs Industry Opportunities and Challenges Table 4. GLP-1 Drugs Industry Restraints Table 5. Global GLP-1 Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global GLP-1 Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global GLP-1 Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global GLP-1 Drugs Sales Market Share by Manufacturers Table 9. Global GLP-1 Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global GLP-1 Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global GLP-1 Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global GLP-1 Drugs Manufacturers, Product Type & Application Table 13. Global GLP-1 Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Albiglutide Table 17. Major Manufacturers of Exenatide Table 18. Major Manufacturers of Beinaglutide Table 19. Major Manufacturers of Dulaglutide Table 20. Major Manufacturers of Liraglutide Table 21. Major Manufacturers of Lixisenatide Table 22. Major Manufacturers of Semaglutide Table 23. Global GLP-1 Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global GLP-1 Drugs Sales by Type (2021-2026) & (K Units) Table 25. Global GLP-1 Drugs Sales by Type (2027-2032) & (K Units) Table 26. Global GLP-1 Drugs Sales Market Share by Type (2021-2026) Table 27. Global GLP-1 Drugs Sales Market Share by Type (2027-2032) Table 28. Global GLP-1 Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 29. Global GLP-1 Drugs Revenue by Type (2021-2026) & (K Units) Table 30. Global GLP-1 Drugs Revenue by Type (2027-2032) & (K Units) Table 31. Global GLP-1 Drugs Revenue Market Share by Type (2021-2026) Table 32. Global GLP-1 Drugs Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Type 2 Diabetes Table 34. Major Manufacturers of Obesity Table 35. Global GLP-1 Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global GLP-1 Drugs Sales by Application (2021-2026) & (K Units) Table 37. Global GLP-1 Drugs Sales by Application (2027-2032) & (K Units) Table 38. Global GLP-1 Drugs Sales Market Share by Application (2021-2026) Table 39. Global GLP-1 Drugs Sales Market Share by Application (2027-2032) Table 40. Global GLP-1 Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 41. Global GLP-1 Drugs Revenue by Application (2021-2026) & (K Units) Table 42. Global GLP-1 Drugs Revenue by Application (2027-2032) & (K Units) Table 43. Global GLP-1 Drugs Revenue Market Share by Application (2021-2026) Table 44. Global GLP-1 Drugs Revenue Market Share by Application (2027-2032) Table 45. Global GLP-1 Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 46. Global GLP-1 Drugs Sales by Region (2021-2026) & (K Units) Table 47. Global GLP-1 Drugs Sales Market Share by Region (2021-2026) Table 48. Global GLP-1 Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 49. Global GLP-1 Drugs Sales Forecasted Market Share by Region (2027-2032) Table 50. North America GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. North America GLP-1 Drugs Sales by Country (2021-2026) & (K Units) Table 52. North America GLP-1 Drugs Sales by Country (2027-2032) & (K Units) Table 53. Europe GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Europe GLP-1 Drugs Sales by Country (2021-2026) & (K Units) Table 55. Europe GLP-1 Drugs Sales by Country (2027-2032) & (K Units) Table 56. Asia Pacific GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. Asia Pacific GLP-1 Drugs Sales by Country (2021-2026) & (K Units) Table 58. Asia Pacific GLP-1 Drugs Sales by Country (2027-2032) & (K Units) Table 59. South America, Middle East and Africa GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. South America, Middle East and Africa GLP-1 Drugs Sales by Country (2021-2026) & (K Units) Table 61. South America, Middle East and Africa GLP-1 Drugs Sales by Country (2027-2032) & (K Units) Table 62. Global GLP-1 Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 63. Global GLP-1 Drugs Revenue by Region (2021-2026) & (US$ Million) Table 64. Global GLP-1 Drugs Revenue by Region (2027-2032) & (US$ Million) Table 65. Global GLP-1 Drugs Revenue Market Share by Region (2021-2026) Table 66. Global GLP-1 Drugs Revenue Market Share by Region (2027-2032) Table 67. AstraZeneca Company Information Table 68. AstraZeneca Business Overview Table 69. AstraZeneca GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AstraZeneca GLP-1 Drugs Product Portfolio Table 71. AstraZeneca Recent Development Table 72. Eli Lilly Company Information Table 73. Eli Lilly Business Overview Table 74. Eli Lilly GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Eli Lilly GLP-1 Drugs Product Portfolio Table 76. Eli Lilly Recent Development Table 77. GSK Company Information Table 78. GSK Business Overview Table 79. GSK GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. GSK GLP-1 Drugs Product Portfolio Table 81. GSK Recent Development Table 82. Novo Nordisk Company Information Table 83. Novo Nordisk Business Overview Table 84. Novo Nordisk GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Novo Nordisk GLP-1 Drugs Product Portfolio Table 86. Novo Nordisk Recent Development Table 87. Sanofi Company Information Table 88. Sanofi Business Overview Table 89. Sanofi GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Sanofi GLP-1 Drugs Product Portfolio Table 91. Sanofi Recent Development Table 92. Shanghai Renhui Biopharmaceutical Company Information Table 93. Shanghai Renhui Biopharmaceutical Business Overview Table 94. Shanghai Renhui Biopharmaceutical GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Shanghai Renhui Biopharmaceutical GLP-1 Drugs Product Portfolio Table 96. Shanghai Renhui Biopharmaceutical Recent Development Table 97. Sino Biopharm Company Information Table 98. Sino Biopharm Business Overview Table 99. Sino Biopharm GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. Sino Biopharm GLP-1 Drugs Product Portfolio Table 101. Sino Biopharm Recent Development Table 102. Huadong Medicine Company Information Table 103. Huadong Medicine Business Overview Table 104. Huadong Medicine GLP-1 Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Huadong Medicine GLP-1 Drugs Product Portfolio Table 106. Huadong Medicine Recent Development Table 107. Key Raw Materials Table 108. Raw Materials Key Suppliers Table 109. GLP-1 Drugs Distributors List Table 110. GLP-1 Drugs Customers List Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. GLP-1 Drugs Product Image Figure 2. Global GLP-1 Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Drugs Sales (2021-2032) & (K Units) Figure 5. Global GLP-1 Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 GLP-1 Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Albiglutide Image Figure 9. Exenatide Image Figure 10. Beinaglutide Image Figure 11. Dulaglutide Image Figure 12. Liraglutide Image Figure 13. Lixisenatide Image Figure 14. Semaglutide Image Figure 15. Global GLP-1 Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global GLP-1 Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global GLP-1 Drugs Sales Market Share by Type (2021-2032) Figure 18. Global GLP-1 Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global GLP-1 Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global GLP-1 Drugs Revenue Market Share by Type (2021-2032) Figure 21. Type 2 Diabetes Image Figure 22. Obesity Image Figure 23. Global GLP-1 Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global GLP-1 Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 25. Global GLP-1 Drugs Sales Market Share by Application (2021-2032) Figure 26. Global GLP-1 Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 27. Global GLP-1 Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 28. Global GLP-1 Drugs Revenue Market Share by Application (2021-2032) Figure 29. North America GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. North America GLP-1 Drugs Sales Market Share by Country (2021-2032) Figure 31. U.S. GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Canada GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Mexico GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Europe GLP-1 Drugs Sales Market Share by Country (2021-2032) Figure 36. Germany GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. France GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. U.K. GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Italy GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Netherlands GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Asia Pacific GLP-1 Drugs Sales Market Share by Country (2021-2032) Figure 43. China GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Japan GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South Korea GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Southeast Asia GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. India GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Australia GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South America, Middle East and Africa GLP-1 Drugs Sales Market Share by Country (2021-2032) Figure 51. Brazil GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. South Africa GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Saudi Arabia GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Turkey GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Argentina GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. UAE GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Egypt GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Chile GLP-1 Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 59. Global GLP-1 Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Global GLP-1 Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 61. North America GLP-1 Drugs Revenue (2021-2032) & (US$ Million) Figure 62. North America GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe GLP-1 Drugs Revenue (2021-2032) & (US$ Million) Figure 64. Europe GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Asia-Pacific GLP-1 Drugs Revenue (2021-2032) & (US$ Million) Figure 66. Asia-Pacific GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. South America, Middle East and Africa GLP-1 Drugs Revenue (2021-2032) & (US$ Million) Figure 68. South America, Middle East and Africa GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 69. GLP-1 Drugs Value Chain Figure 70. Manufacturing Cost Structure Figure 71. GLP-1 Drugs Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Albiglutide
  • Exenatide
  • Beinaglutide
  • Dulaglutide
  • Liraglutide
  • Lixisenatide
  • Semaglutide
Applications
  • Type 2 Diabetes
  • Obesity
Companies covered
  • AstraZeneca
  • Eli Lilly
  • GSK
  • Novo Nordisk
  • Sanofi
  • Shanghai Renhui Biopharmaceutical
  • Sino Biopharm
  • Huadong Medicine

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global GLP-1 Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global GLP-1 Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global GLP-1 Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global GLP-1 Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global GLP-1 Drugs Market Dynamics
  1. 2.1 GLP-1 Drugs Industry Trends
  2. 2.2 GLP-1 Drugs Industry Drivers
  3. 2.3 GLP-1 Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drugs Industry Restraints
3 GLP-1 Drugs Market by Manufacturers
  1. 3.1 Global GLP-1 Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global GLP-1 Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global GLP-1 Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global GLP-1 Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global GLP-1 Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global GLP-1 Drugs Manufacturers, Product Type & Application
  7. 3.7 Global GLP-1 Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global GLP-1 Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 GLP-1 Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 GLP-1 Drugs Tier 1, Tier 2, and Tier 3
4 GLP-1 Drugs Market by Type
  1. 4.1 GLP-1 Drugs Type Introduction
  2. 4.1.1 Albiglutide
  3. 4.1.2 Exenatide
  4. 4.1.3 Beinaglutide
  5. 4.1.4 Dulaglutide
  6. 4.1.5 Liraglutide
  7. 4.1.6 Lixisenatide
  8. 4.1.7 Semaglutide
  9. 4.2 Global GLP-1 Drugs Sales by Type
  10. 4.2.1 Global GLP-1 Drugs Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global GLP-1 Drugs Sales by Type (2021-2032)
  12. 4.2.3 Global GLP-1 Drugs Sales Market Share by Type (2021-2032)
  13. 4.3 Global GLP-1 Drugs Revenue by Type
  14. 4.3.1 Global GLP-1 Drugs Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global GLP-1 Drugs Revenue by Type (2021-2032)
  16. 4.3.3 Global GLP-1 Drugs Revenue Market Share by Type (2021-2032)
5 GLP-1 Drugs Market by Application
  1. 5.1 GLP-1 Drugs Application Introduction
  2. 5.1.1 Type 2 Diabetes
  3. 5.1.2 Obesity
  4. 5.2 Global GLP-1 Drugs Sales by Application
  5. 5.2.1 Global GLP-1 Drugs Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global GLP-1 Drugs Sales by Application (2021-2032)
  7. 5.2.3 Global GLP-1 Drugs Sales Market Share by Application (2021-2032)
  8. 5.3 Global GLP-1 Drugs Revenue by Application
  9. 5.3.1 Global GLP-1 Drugs Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global GLP-1 Drugs Revenue by Application (2021-2032)
  11. 5.3.3 Global GLP-1 Drugs Revenue Market Share by Application (2021-2032)
6 Global GLP-1 Drugs Sales by Region
  1. 6.1 Global GLP-1 Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global GLP-1 Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America GLP-1 Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe GLP-1 Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific GLP-1 Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa GLP-1 Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa GLP-1 Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global GLP-1 Drugs Revenue by Region
  1. 7.1 Global GLP-1 Drugs Revenue by Region
  2. 7.1.1 Global GLP-1 Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global GLP-1 Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global GLP-1 Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global GLP-1 Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America GLP-1 Drugs Revenue (2021-2032)
  8. 7.2.2 North America GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe GLP-1 Drugs Revenue (2021-2032)
  11. 7.3.2 Europe GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific GLP-1 Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa GLP-1 Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa GLP-1 Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca GLP-1 Drugs Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 Eli Lilly
  8. 8.2.1 Eli Lilly Company Information
  9. 8.2.2 Eli Lilly Business Overview
  10. 8.2.3 Eli Lilly GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly GLP-1 Drugs Product Portfolio
  12. 8.2.5 Eli Lilly Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 GSK GLP-1 Drugs Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Novo Nordisk
  20. 8.4.1 Novo Nordisk Company Information
  21. 8.4.2 Novo Nordisk Business Overview
  22. 8.4.3 Novo Nordisk GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novo Nordisk GLP-1 Drugs Product Portfolio
  24. 8.4.5 Novo Nordisk Recent Developments
  25. 8.5 Sanofi
  26. 8.5.1 Sanofi Company Information
  27. 8.5.2 Sanofi Business Overview
  28. 8.5.3 Sanofi GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sanofi GLP-1 Drugs Product Portfolio
  30. 8.5.5 Sanofi Recent Developments
  31. 8.6 Shanghai Renhui Biopharmaceutical
  32. 8.6.1 Shanghai Renhui Biopharmaceutical Company Information
  33. 8.6.2 Shanghai Renhui Biopharmaceutical Business Overview
  34. 8.6.3 Shanghai Renhui Biopharmaceutical GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shanghai Renhui Biopharmaceutical GLP-1 Drugs Product Portfolio
  36. 8.6.5 Shanghai Renhui Biopharmaceutical Recent Developments
  37. 8.7 Sino Biopharm
  38. 8.7.1 Sino Biopharm Company Information
  39. 8.7.2 Sino Biopharm Business Overview
  40. 8.7.3 Sino Biopharm GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Sino Biopharm GLP-1 Drugs Product Portfolio
  42. 8.7.5 Sino Biopharm Recent Developments
  43. 8.8 Huadong Medicine
  44. 8.8.1 Huadong Medicine Company Information
  45. 8.8.2 Huadong Medicine Business Overview
  46. 8.8.3 Huadong Medicine GLP-1 Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Huadong Medicine GLP-1 Drugs Product Portfolio
  48. 8.8.5 Huadong Medicine Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Drugs Value Chain Analysis
  2. 9.1.1 GLP-1 Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Drugs Production Mode & Process
  6. 9.2 GLP-1 Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Drugs Distributors
  9. 9.2.3 GLP-1 Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst